Companies /Healthcare

Novo Nordisk A/S

NYSE: NVO Drug Manufacturers - General
$37.82
▼ $1.05 (−2.70%) today
Markets closed · 7:27pm ET

24/7 Wall St. View

NVO at a Glance

Valuation
Market cap
$171.3B
P/E ratio
9.8
Dividend yield
4.62%
Profitability
Revenue (TTM)
$333.7B
Profit margin
33.9%
EPS (TTM)
$3.96
Price
52-week range
$34 – $61
24/7 target
$47.44
Street target
$45.74

Headquartered in Novo Alle 1, Bagsvaerd Fiscal year ends December NYSE: NVO novonordisk.com

About Novo Nordisk

Novo Nordisk A/S is a global healthcare company focused on serious chronic diseases, with deep expertise in diabetes and obesity care. The company develops, manufactures, and markets a portfolio of GLP-1-based therapies including Ozempic, Wegovy, Rybelsus, and Victoza for diabetes and weight management, as well as Saxenda for obesity. Novo Nordisk also operates in rare disease therapeutics. The company's B shares trade on Nasdaq Copenhagen and its American Depositary Receipts (ADRs) trade on the New York Stock Exchange under the ticker NVO. Novo Nordisk employs approximately 66,700 people across 80 countries and markets its products in around 170 countries. The company's pipeline includes research into next-generation treatments for obesity and metabolic diseases, though its Q2 2026 filing noted a significant impairment of the monlunabant pipeline asset. Updated

Latest Activity

Cramer is calling a mispricing in the obesity drug race, arguing Lilly's latest wins over Novo Nordisk have not been paid for by the market yet.

LLY tons of powerful news versus Novo on weight loss drugs. Being ignored
  • Replies11
  • Reposts2
  • Likes41

NVO Coverage

Frequently Asked Questions

What does Novo Nordisk do?

Novo Nordisk A/S is a global healthcare company focused on serious chronic diseases, with deep expertise in diabetes and obesity care.

What is the NVO stock price target?

24/7 Wall St.'s 12-month price target for NVO is $47.44, rated Buy. The Wall Street consensus target is $45.74. NVO price prediction →